title: Rifampin-containing regimens for community-associated skin infection: a hazard without known benefit.
authors.forename: Loren G
authors.initials: LG
authors.lastname: Miller
authors.forename: Helen
authors.initials: H
authors.lastname: Boucher
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000904:Antibiotics, Antitubercular / Q000009:adverse effects / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005667:Furunculosis / Q000188:drug therapy*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage
chemical_list: D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D012293:Rifampin